Predictive Factors for Successful Operative Hysteroscopy Using Tissue Removal Device (TruClear System) Without Anesthesia

Sponsor
Assaf-Harofeh Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05722028
Collaborator
(none)
70
1
13
5.4

Study Details

Study Description

Brief Summary

Background: Small-diameter operative hysteroscopes may allow to perform operative hysteroscopy without general anesthesia in selected patients. One of these instruments is the tissue removal device (TRD), which resects and removes intrauterine pathology such as endometrial polyps and retained products of conception (RPOC) with a diameter of ¬6 mm.

Objective: To assess the success rate and intraoperative pain of patients undergoing operative hysteroscopy without anesthesia with the TRD (TruClear Elite Mini-Hysteroscope) for removal of endometrial polyps or RPOC.

Methods: Prospective observational study. Participation in the study was offered to patients diagnosed with uterine polyps or RPOC on office diagnostic hysteroscopy. The patients filled out a digital questionnaire before and after the operation. A successful procedure was defined as complete hysteroscopic removal of the uterine pathology using the TruClear system. Oral 400 mcg misoprostol 12 hours before the procedure was prescribed for cervical ripening.

Condition or Disease Intervention/Treatment Phase
  • Procedure: hysteroscopy

Study Design

Study Type:
Observational
Anticipated Enrollment :
70 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Predictive Factors for Successful Operative Hysteroscopy Using Tissue Removal Device (TruClear System) Without Anesthesia
Actual Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Aug 31, 2023
Anticipated Study Completion Date :
Aug 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Patients with benign uterine findings (polyp / retained products of conception)

Female patients undergoing diagnostic hysteroscopy with a diagnosis of uterine polyp or retained products of conception. These patients are then invited to a surgical office procedure without anaesthesia to remove these findings.

Procedure: hysteroscopy
Surgical hysteroscopy without anaesthesia for removal of uterine polyp / retained products of conception.

Outcome Measures

Primary Outcome Measures

  1. Procedure completed successfully [Immediately after procedure]

    Was the procedure completed - yes/no

Secondary Outcome Measures

  1. Prevalence of VAS (pain scale) > 5 during procedure [Immediately after procedure]

    VAS (Visual analogue scale 0-10, most painful 10) grading by the patient

  2. Prevalence of VAS (pain scale) > 5, five minutes after procedure [5 minutes after procedure]

    VAS (Visual analogue scale 0-10, most painful 10) grading by the patient

  3. Acceptable procedure by the patient [5 minutes after procedure]

    Was the procedure acceptable by the patient (1-4 when 1 is most acceptable)

  4. Recommended procedure by the patient [5 minutes after procedure]

    Would the patient recommend her acquittance the procedure in this outline (1-5, most recommended 5) aquitance (1-5)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Inclusion Criteria:
  • Diagnosis of polyp or retained products of conception in diagnostic hysteroscopy.

  • Medical need to remove the finding according to accepted criteria.

  • Patient's consent to the removal of the finding in a procedure without anesthesia.

  • Patient's consent to participate in the study.

Exclusion Criteria:
  • Any indication for performing the procedure under anesthesia in an operating room, such as:
  1. Medical background requiring operation in an operating room.

  2. Personal / mental background requiring procedure under general anesthesia.

  3. Cervical stenosis

  4. Previous failure to remove the finding in a procedure without anesthesia

  5. Lack of response to performing the operation without anesthesia

  • The lack of response to participate in the study

  • A known diagnosis of malignancy from a previous sample of the polyp or endometrium

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shamir medical center Zrifin Israel

Sponsors and Collaborators

  • Assaf-Harofeh Medical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Maayan Gal, investigator, Assaf-Harofeh Medical Center
ClinicalTrials.gov Identifier:
NCT05722028
Other Study ID Numbers:
  • 123456
First Posted:
Feb 10, 2023
Last Update Posted:
Feb 10, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes

Study Results

No Results Posted as of Feb 10, 2023